Sellas Life Sciences Group Inc (SLS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.60B
Last updated: Nov 17, 2026 at 11:06 AM ET
Sellas Life Sciences Group Inc (SLS) Earnings: Report Dates and Results
Sellas Life Sciences Group (SLS) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Sellas Life Sciences Group reported EPS of -$0.05, in line with the -$0.05 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SLS has an expected report date of Mar 17, 2027.
Earnings History
Of the 38 quarters below that had an estimate, SLS beat 20, missed 15 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 377.78% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.05 | -$0.05 | -$0.05 - -$0.05 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.05 | -$0.04 | -$0.05 - -$0.04 | -25.00% | Miss | N/A | 2 | 1 up, 1 down | Aug 11, 2026 | N/A |
| Mar 31, 2026 | -$0.05 | -$0.07 | -$0.08 - -$0.04 | +30.43% | Beat | N/A | 2 | 1 up, 0 down | May 12, 2026 | N/A |
| Dec 31, 2025 | -$0.05 | -$0.06 | -$0.09 - -$0.05 | +16.67% | Beat | N/A | 3 | 1 up, 0 down | Mar 19, 2026 | N/A |
| Sep 30, 2025 | -$0.06 | -$0.08 | -$0.10 - -$0.06 | +25.00% | Beat | N/A | 3 | 0 up, 0 down | Nov 12, 2025 | N/A |
| Jun 30, 2025 | -$0.07 | -$0.08 | -$0.10 - -$0.06 | +12.50% | Beat | N/A | 3 | 0 up, 0 down | Aug 12, 2025 | N/A |
| Mar 31, 2025 | -$0.07 | -$0.11 | -$0.12 - -$0.09 | +36.36% | Beat | N/A | 3 | 1 up, 0 down | May 13, 2025 | N/A |
| Dec 31, 2024 | -$0.08 | -$0.11 | -$0.12 - -$0.09 | +25.02% | Beat | N/A | 3 | 2 up, 1 down | Mar 20, 2025 | N/A |
| Sep 30, 2024 | -$0.10 | -$0.13 | -$0.15 - -$0.11 | +23.08% | Beat | N/A | 2 | 0 up, 0 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$0.13 | -$0.17 | -$0.17 - -$0.16 | +23.53% | Beat | N/A | 2 | 0 up, 0 down | Aug 13, 2024 | N/A |
| Mar 31, 2024 | -$0.21 | -$0.16 | -$0.16 - -$0.16 | -31.25% | Miss | N/A | 1 | 0 up, 0 down | May 14, 2024 | N/A |
| Dec 31, 2023 | -$0.25 | $0.09 | -$0.27 - $0.12 | -377.78% | Miss | N/A | 4 | 0 up, 0 down | Mar 28, 2024 | N/A |
| Sep 30, 2023 | -$0.33 | $0.02 | -$0.32 - $0.15 | N/A | N/A | N/A | 4 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.31 | -$0.35 | -$0.40 - -$0.29 | +11.43% | Beat | N/A | 4 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.47 | -$0.29 | -$0.29 - -$0.29 | -62.07% | Miss | N/A | 3 | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.43 | -$0.32 | -$0.36 - -$0.26 | -34.38% | Miss | N/A | 3 | 0 up, 0 down | Mar 16, 2023 | N/A |
| Sep 30, 2022 | -$0.34 | -$0.39 | -$0.42 - -$0.36 | +12.82% | Beat | N/A | 3 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$0.42 | -$0.37 | N/A | -13.51% | Miss | N/A | N/A | 0 up, 0 down | Aug 11, 2022 | N/A |
| Mar 31, 2022 | -$0.42 | -$0.42 | N/A | 0.00% | In line | N/A | 1 | 0 up, 0 down | May 12, 2022 | $1.00M |
| Dec 31, 2021 | -$0.42 | -$0.41 | -$0.45 - -$0.34 | -2.44% | Miss | N/A | 3 | 0 up, 0 down | Mar 31, 2022 | N/A |
| Sep 30, 2021 | -$0.45 | -$0.34 | -$0.43 - -$0.30 | -32.35% | Miss | N/A | 3 | 1 up, 0 down | Nov 12, 2021 | N/A |
| Jun 30, 2021 | -$0.30 | -$0.39 | -$0.52 - -$0.29 | +23.08% | Beat | N/A | 3 | N/A | Aug 12, 2021 | $1.90M |
| Mar 31, 2021 | -$0.16 | -$0.36 | -$0.36 - -$0.18 | +55.56% | Beat | N/A | 2 | N/A | May 13, 2021 | $5.70M |
| Dec 31, 2020 | -$0.28 | -$0.28 | -$0.36 - -$0.19 | 0.00% | In line | N/A | 2 | N/A | Mar 23, 2021 | $1.90M |
| Sep 30, 2020 | -$0.53 | -$0.34 | -$0.34 - -$0.27 | -55.88% | Miss | N/A | 2 | N/A | Nov 13, 2020 | N/A |
| Jun 30, 2020 | -$0.63 | -$0.64 | -$0.64 - -$0.64 | +1.56% | Beat | N/A | 1 | N/A | Aug 13, 2020 | N/A |
| Mar 31, 2020 | -$0.63 | -$0.68 | N/A | +7.35% | Beat | N/A | N/A | N/A | May 14, 2020 | N/A |
| Dec 31, 2019 | -$1.54 | -$0.72 | -$0.87 - -$0.58 | -113.89% | Miss | N/A | 2 | N/A | Mar 13, 2020 | N/A |
| Sep 30, 2019 | -$0.96 | -$1.00 | -$1.00 - -$1.00 | +4.00% | Beat | N/A | 1 | N/A | Nov 14, 2019 | N/A |
| Jun 30, 2019 | -$6.19 | -$9.00 | -$9.00 - -$9.00 | +31.22% | Beat | N/A | 1 | N/A | Aug 14, 2019 | N/A |
| Mar 31, 2019 | -$9.71 | -$10.25 | -$11.50 - -$9.00 | +5.27% | Beat | N/A | 2 | N/A | May 15, 2019 | N/A |
| Dec 31, 2018 | -$8.50 | -$11.75 | -$15.50 - -$8.00 | +27.66% | Beat | N/A | 2 | N/A | Mar 22, 2019 | N/A |
| Sep 30, 2018 | -$26.50 | -$20.25 | -$20.50 - -$18.00 | -30.86% | Miss | N/A | 2 | N/A | Nov 15, 2018 | N/A |
| Jun 30, 2018 | -$63.00 | -$51.50 | -$54.00 - -$49.00 | -22.33% | Miss | N/A | 2 | N/A | Aug 15, 2018 | N/A |
| Mar 31, 2018 | -$83.50 | -$46.50 | -$46.50 - -$46.50 | -79.57% | Miss | N/A | 1 | N/A | Apr 13, 2018 | N/A |
| Dec 31, 2017 | -$49.50 | -$1.06 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 15, 2018 | N/A |
| Sep 30, 2017 | -$30.00 | -$225.00 | N/A | +86.67% | Beat | N/A | N/A | N/A | Nov 9, 2017 | N/A |
| Jun 30, 2017 | -$330.00 | -$270.00 | N/A | -22.22% | Miss | -127.5% | N/A | N/A | Aug 14, 2017 | N/A |
| Mar 31, 2017 | -$675.00 | -$330.00 | N/A | -104.55% | Miss | N/A | N/A | N/A | May 10, 2017 | N/A |
| Dec 31, 2016 | -$735.00 | -$780.00 | N/A | +5.77% | Beat | N/A | N/A | N/A | Mar 15, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.25, after -$0.52 the year before. It was -$3,135.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.25 | N/A |
| Dec 31, 2024 | -$0.52 | N/A |
| Dec 31, 2023 | -$1.36 | N/A |
| Dec 31, 2022 | -$1.61 | N/A |
| Dec 31, 2021 | -$1.33 | N/A |
| Dec 31, 2020 | -$2.07 | N/A |
| Dec 31, 2019 | -$18.40 | N/A |
| Dec 31, 2018 | -$181.50 | N/A |
| Dec 31, 2017 | -$1,084.50 | N/A |
| Dec 31, 2016 | -$3,135.00 | N/A |
Frequently Asked Questions About SLS
When is Sellas Life Sciences Group's next earnings date?
Sellas Life Sciences Group's next earnings report is expected for Mar 17, 2027.
Did SLS beat earnings estimates last quarter?
Sellas Life Sciences Group reported EPS of -$0.05 for the quarter ended Sep 30, 2026, in line with the -$0.05 estimate.
What EPS do analysts expect from SLS next quarter?
The consensus EPS estimate for Sellas Life Sciences Group for the quarter ending Dec 31, 2026 is -$0.05 from 3 analysts, with estimates from -$0.05 to -$0.05.
How often does SLS beat earnings estimates?
Sellas Life Sciences Group beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +15.12%.
SLS pages: Overview, Earnings, Forecast, Financials, Competitors